BAX Quote, Financials, Valuation and Earnings

Becton Dickinson & has a net margin of 4.8% compared to Baxter International's net margin of 5.84%. Baxter International's return on equity of -7.38% beat Becton Dickinson &'s return on equity of 5.86%.

Baxter International has a consensus price target of $38.09, signalling upside risk potential of 33.52%. On the other hand Becton Dickinson & has an analysts' consensus of $216.04 which suggests that it could grow by 22%. Given that Baxter International has higher upside potential than Becton Dickinson &, analysts believe Baxter International is more attractive than Becton Dickinson &.

Baxter International has a beta of 0.610, which suggesting that the stock is 38.958% less volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.252, suggesting its less volatile than the S&P 500 by 74.847%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.8%. Becton Dickinson & offers a yield of 2.3% to investors and pays a quarterly dividend of $1.04 per share. Baxter International pays -90.91% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.6B, which are smaller than Becton Dickinson & quarterly revenues of $5.3B. Baxter International's net income of $126M is lower than Becton Dickinson &'s net income of $308M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Becton Dickinson &'s PE ratio is 33.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.23x versus 2.46x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 4.8% compared to Baxter International's net margin of 14.45%. Baxter International's return on equity of -7.38% beat Boston Scientific's return on equity of 9.57%.

Baxter International has a consensus price target of $38.09, signalling upside risk potential of 33.52%. On the other hand Boston Scientific has an analysts' consensus of $117.45 which suggests that it could grow by 12.58%. Given that Baxter International has higher upside potential than Boston Scientific, analysts believe Baxter International is more attractive than Boston Scientific.

Baxter International has a beta of 0.610, which suggesting that the stock is 38.958% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.134%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.8%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International pays -90.91% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Baxter International quarterly revenues are $2.6B, which are smaller than Boston Scientific quarterly revenues of $4.7B. Baxter International's net income of $126M is lower than Boston Scientific's net income of $674M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Boston Scientific's PE ratio is 76.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.23x versus 8.85x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 4.8% compared to Baxter International's net margin of 6.22%. Baxter International's return on equity of -7.38% beat Insulet's return on equity of 36.9%.

Baxter International has a consensus price target of $38.09, signalling upside risk potential of 33.52%. On the other hand Insulet has an analysts' consensus of $336.85 which suggests that it could grow by 15.36%. Given that Baxter International has higher upside potential than Insulet, analysts believe Baxter International is more attractive than Insulet.

Baxter International has a beta of 0.610, which suggesting that the stock is 38.958% less volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.8%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International pays -90.91% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Baxter International quarterly revenues are $2.6B, which are larger than Insulet quarterly revenues of $569M. Baxter International's net income of $126M is higher than Insulet's net income of $35.4M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Insulet's PE ratio is 52.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.23x versus 9.82x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 4.8% compared to Baxter International's net margin of 11.15%. Baxter International's return on equity of -7.38% beat Stryker's return on equity of 14.2%.

Baxter International has a consensus price target of $38.09, signalling upside risk potential of 33.52%. On the other hand Stryker has an analysts' consensus of $422.71 which suggests that it could grow by 7.98%. Given that Baxter International has higher upside potential than Stryker, analysts believe Baxter International is more attractive than Stryker.

Baxter International has a beta of 0.610, which suggesting that the stock is 38.958% less volatile than S&P 500. In comparison Stryker has a beta of 0.915, suggesting its less volatile than the S&P 500 by 8.528%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.8%. Stryker offers a yield of 0.85% to investors and pays a quarterly dividend of $0.84 per share. Baxter International pays -90.91% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.6B, which are smaller than Stryker quarterly revenues of $5.9B. Baxter International's net income of $126M is lower than Stryker's net income of $654M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Stryker's PE ratio is 52.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.23x versus 6.51x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.